ISSN: 2161-1025
Kuladip Jana, Bhaswati Banerjee and Pravat Kumar Parida
An enormous body of evidence supports the activation of caspases may be responsible for the neurodegeneration associated with Alzheimer’s disease (AD) and for that reason, caspases are potential therapeutic targets for the management of this disorder. However, till date, the studies testing with prospective role of caspase inhibitors for the treatment of AD have yet to be realized. Obviously, this is due to the potential side effects due to long term use of caspase inhibitors. In addition, a further assessment is warned in relation to the therapeutic efficacy and stress of targeting caspase inhibition with the potential caspase inhibitors and its improved delivery system to the brain in the treatment of AD.